Drug Profile
Research programme: CC-chemokine receptor 3 antagonists - Millennium/Roche Bioscience
Alternative Names: CCR3 antagonists research programme - Millennium/Roche BioscienceLatest Information Update: 23 Aug 2002
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Developer Millennium Pharmaceuticals; Roche Palo Alto LLC
- Class
- Mechanism of Action CCR3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Asthma; Hypersensitivity
Most Recent Events
- 26 Jan 2000 LeukoSite has been merged into Millennium Pharmaceuticals
- 05 Jun 1998 New profile
- 05 Jun 1998 Preclinical development for Allergy in USA (PO)